SCHEMBL20093480

SCHEMBL20093480

Nc1ncnc2[nH]nc(-c3cn[nH]c3)c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 5/20 0.39
RET P07949 1/20 0.39
PI4KA P42356 1/20 0.39
XDH P47989 1/20 0.39
PI4K2B Q8TCG2 1/20 0.39
PI4K2A Q9BTU6 1/20 0.39
PI4KB Q9UBF8 1/20 0.39
PIK3CG P48736 5/20 0.38
PIM1 P11309 2/20 0.36
ADK P55263 1/20 0.36
PIK3CD O00329 4/20 0.35
PIK3CA P42336 4/20 0.35
PIK3CB P42338 4/20 0.35
PRKDC P78527 4/20 0.35
MAPK1 P28482 1/20 0.34
NTRK1 P04629 1/20 0.34
PRMT5 O14744 1/20 0.34
ABL1 P00519 1/20 0.33
SRC P12931 1/20 0.33
AKT1 P31749 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22275990 0.79 PIK3CD (0.39) PI4KBPIK3CGPIK3CDPIK3CAPIK3CB
SCHEMBL20093453 0.79 PIK3CD (0.46) LRRK2RETPI4KAXDHPI4K2B
SCHEMBL30387175 0.76 PIK3CD (0.55) PI4KBPIK3CGPIK3CDPIK3CAPIK3CB
SCHEMBL408618 0.76 PIK3CD (0.55) LRRK2RETPIK3CGPIK3CDPIK3CA
SCHEMBL3782102 0.73 PIK3CD (0.57) RETPI4KBPIK3CGPIK3CDPIK3CA
SCHEMBL5065122 0.73 PIK3CD (0.57) LRRK2RETPIK3CGADKPIK3CD
SCHEMBL11325 0.73 PIK3CG (0.49) PI4KBPIK3CGPIK3CDPIK3CAPIK3CB
SCHEMBL3715031 0.73 SRC (0.57) PIK3CGADKPIK3CDPIK3CAPIK3CB
SCHEMBL15613778 0.73 PIK3CD (0.42) PIK3CGADKPIK3CDPIK3CAPIK3CB
SCHEMBL19414400 0.73 CYP1A1 (0.47) PI4KBPIK3CGPIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11020399-B2 Intermediates useful in the synthesis of compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2021-06-01 US disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 US disclosed
US-20190282581-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2019-09-19 US disclosed
US-10322130-B2 Substituted chromenones as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-06-18 US disclosed
US-20190105324-A9 SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2019-04-11 US disclosed
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2018-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11020399-B2 Intermediates useful in the synthesis of compounds as modulators of protein kinases MAP4K2, MAP3K20, MAP3K1 LRRK2 1051/4885RET 500/4885PI4KA 217/4885
US-20190105324-A9 SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKAR2B LRRK2 383/4885RET 656/4885PI4KA 107/4885
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB LRRK2 317/4885RET 733/4885PI4KA 82/4885
US-20190282581-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB LRRK2 317/4885RET 733/4885PI4KA 82/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB LRRK2 290/4885RET 1007/4885PI4KA 98/4885
US-10322130-B2 Substituted chromenones as modulators of protein kinases MAP3K1, CSNK1A1, MAP3K2 LRRK2 455/4885RET 627/4885PI4KA 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.